Ambry Genetics and Invicro partner to offer customized genomics and imaging services for the pharmaceutical and biotechnology industry, exhibiting profound emphasis on Oncology and neurodegenerative diseases.
Invicro and Ambry Genetics were acquired by Konica Minolta in 2017 as a part of Konica Minolta’s expansion into the clinical healthcare space, with a special emphasis on precision medicine. Konica Minolta’s mission is to improve patient care, from Oncology disease diagnosis to drug discovery to companion diagnostic development.
Dr. Jack Hoppin, Co-Founder and CEO of Invicro said “We are excited to join the Konica Minolta precision medicine family and to have this opportunity to integrate our research services and informatics platform with the tier-one genomics offerings at Ambry.”
Dr. Phillip Gray, VP of Advanced Genomic Services at Ambry said “Invicro’s imaging platform is an ideal complement to Ambry’s advanced genomics services for a comprehensive solution designed to improve the productivity of the biopharmaceutical industry.”
Image Source: Ambry Genetics